A detailed history of Eagle Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Eagle Asset Management Inc holds 707,663 shares of ABBV stock, worth $129 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares
707,663
Previous 966,355 26.77%
Holding current value
$129 Million
Previous $166 Million 15.69%
% of portfolio
0.84%
Previous 0.92%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $42.4 Million - $51.6 Million
-258,692 Reduced 26.77%
707,663 $140 Million
Q2 2024

Aug 12, 2024

SELL
$154.79 - $180.76 $651,511 - $760,818
-4,209 Reduced 0.43%
966,355 $166 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $3.9 Million - $4.44 Million
-24,390 Reduced 2.45%
970,564 $177 Million
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $4.78 Million - $5.38 Million
-34,741 Reduced 3.37%
994,954 $154 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $3.35 Million - $3.87 Million
-25,049 Reduced 2.37%
1,029,695 $153 Million
Q2 2023

Aug 09, 2023

SELL
$132.51 - $164.9 $2.62 Million - $3.26 Million
-19,798 Reduced 1.84%
1,054,744 $142 Million
Q1 2023

May 08, 2023

BUY
$144.61 - $166.54 $17.3 Million - $19.9 Million
119,530 Added 12.52%
1,074,542 $171 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $888,780 - $1.07 Million
6,426 Added 0.68%
955,012 $154 Million
Q3 2022

Nov 07, 2022

SELL
$134.21 - $153.93 $877,196 - $1.01 Million
-6,536 Reduced 0.68%
948,586 $127 Million
Q2 2022

Aug 10, 2022

SELL
$137.62 - $174.96 $7.72 Million - $9.81 Million
-56,091 Reduced 5.55%
955,122 $146 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $29.8 Million - $37 Million
-226,165 Reduced 18.28%
1,011,213 $164 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $2.38 Million - $3.01 Million
22,125 Added 1.82%
1,237,378 $168 Million
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $8.68 Million - $9.85 Million
81,578 Added 7.2%
1,215,253 $131 Million
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $2.18 Million - $2.43 Million
20,761 Added 1.87%
1,133,675 $128 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $86.2 Million - $94.9 Million
842,576 Added 311.68%
1,112,914 $121 Million
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $1.9 Million - $2.57 Million
23,641 Added 9.58%
270,338 $29 Million
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $430,495 - $505,259
5,011 Added 2.07%
246,697 $21.4 Million
Q2 2020

Aug 12, 2020

SELL
$73.37 - $98.18 $1.76 Million - $2.36 Million
-24,012 Reduced 9.04%
241,686 $23.3 Million
Q1 2020

May 11, 2020

BUY
$64.5 - $97.79 $11.2 Million - $17 Million
173,748 Added 188.96%
265,698 $20.2 Million
Q4 2019

Feb 07, 2020

BUY
$72.13 - $90.25 $2.47 Million - $3.1 Million
34,310 Added 59.52%
91,950 $8.14 Million
Q3 2019

Nov 04, 2019

BUY
$62.98 - $75.72 $32,686 - $39,298
519 Added 0.91%
57,640 $4.36 Million
Q2 2019

Aug 05, 2019

BUY
$65.7 - $83.98 $80,876 - $103,379
1,231 Added 2.2%
57,121 $4.15 Million
Q1 2019

May 01, 2019

BUY
$77.14 - $90.79 $108,535 - $127,741
1,407 Added 2.58%
55,890 $4.5 Million
Q4 2018

Feb 11, 2019

SELL
$77.85 - $96.01 $145,345 - $179,250
-1,867 Reduced 3.31%
54,483 $5.02 Million
Q3 2018

Nov 08, 2018

BUY
$88.91 - $98.84 $104,202 - $115,840
1,172 Added 2.12%
56,350 $5.33 Million
Q2 2018

Aug 07, 2018

BUY
$89.78 - $106.23 $64,282 - $76,060
716 Added 1.31%
55,178 $5.11 Million
Q1 2018

May 09, 2018

BUY
$92.01 - $123.21 $15,181 - $20,329
165 Added 0.3%
54,462 $5.15 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $2.48 Million - $2.72 Million
-27,721 Reduced 33.8%
54,297 $5.96 Million
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $5.73 Million - $7.32 Million
82,018
82,018 $7.41 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $321B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.